KROS Keros Therapeutics, Inc.

QT50

Latest market price

10.76

-0.28-2.54%

Overview Short InterestFilings

KROSQT50Keros Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

10.76-2.54%

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-7.49%$22.97 RARE+1.24%$16.30 NUVB-3.57%$4.59 TRAX-0.07%$45.05 NTLA-6.50%$11.66 ABSI-12.94%$9.69 URGN+5.01%$34.36 MAZE-3.53%$30.37

Snapshot

Index	—	P/E	6.99	EPS (ttm)	1.54	Insider Own	—	Shs Outstand	19.83M	Perf Week	-5.03%

Market Cap	213.34M	Forward P/E	—	EPS next Y	-6.24	Insider Trans	-0.10%	Shs Float	18.15M	Perf Month	-5.28%

Enterprise Value	129.82M	PEG	—	EPS next Q	-0.96			Short Float	6.26%	Perf Quarter	4.98%

Income	87.00M	P/S	0.87	EPS this Y	-340.91%			Short Ratio	5.98	Perf Half Y	-8.11%

Sales	244.00M	P/B	0.81	EPS next Y	—	ROA	-28.91%	Short Interest	1.14M	Perf YTD	-47.15%

Book/sh	13.21	P/C	0.83	EPS next 5Y	—	ROE	-21.40%	52W High	22.55 -52.28%	Perf Year	-28.41%

Cash/sh	13.01	P/FCF	—	EPS past 3/5Y	—	ROIC	-35.25%	52W Low	9.69 11.04%	Perf 3Y	-61.80%

Dividend Est.	—	EV/EBITDA	0.27	Sales past 3/5Y	—	Gross Margin	94.69%	Volatility	5.43% 4.77%	Perf 5Y	-73.35%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	-1388.00%	Oper. Margin	-675.82%	ATR (14)	0.53	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	21.96	Sales Y/Y TTM	-93.97%	Profit Margin	-553.88%	RSI (14)	41.95	Recom	2.41

Dividend Gr. 3/5Y	—	Current Ratio	21.96	EPS Q/Q	-90.79%	SMA20	-4.47%	Beta	1.18	Target Price	20.33

Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-100.00%	SMA50	-4.50%	Rel Volume	0.74	Prev Close	11.04

Employees	92	LT Debt/Eq	0.05	Earnings	Nov 04	SMA200	-10.49%	Avg Volume	187.16K	Price	10.76

IPO Date	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.21% —	Net Debt/EBITDA	-2.60	Volume	139,244	Change	-2.54%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-04-26	Reiterated	H.C. Wainwright	Buy	$20
Aug-04-26	Reiterated	Wells Fargo	Overweight	$18
Aug-04-26	Reiterated	Leerink Partners	Outperform	$23
Jun-10-25	Downgrade	B of A Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-12-24	Downgrade	William Blair	Outperform → Market Perform
Dec-12-24	Downgrade	BTIG	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold

Latest News· Times ET

Oct-22-26

Oct-22-2607:04PM

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stagemarketbeat.com

Oct-20-26

Oct-20-2608:59AM

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayYahoo

Oct-07-26

Oct-07-2601:30PM

Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Yahoo

Oct-05-26

Oct-05-2608:14AM

Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)defenseworld.net

Sep-29-26

Sep-29-2611:21AM

KROS Begins Dosing in Phase II Study With Rinvatercept in DMDzacks.com

08:00AM

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takedaglobenewswire.com

04:04AM

Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical TrialBenzinga

Sep-28-26

Sep-28-2608:00AM

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDglobenewswire.com

Sep-10-26

Sep-10-2612:06PM

Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering PartnersBenzinga

Sep-08-26

Sep-08-2604:01PM

Keros Therapeutics Announces $5 Million Share Repurchase Authorizationglobenewswire.com

12:02PM

Keros Therapeutics Reveals $5M Share Repurchase AuthorizationBenzinga

Sep-02-26

Sep-02-2612:31PM

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?zacks.com

04:22AM

Hsbc Holdings PLC Makes New $761,000 Investment in Keros Therapeutics, Inc. $KROSdefenseworld.net

Aug-24-26

Aug-24-2601:56PM

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?zacks.com

01:56PM

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weakzacks.com

Company

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	244	4	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	2	0	0	—	—	—	—	—
Gross Profit	243	4	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	47	41	35	—	—	—	—	—
Research and Development	130	174	135	—	—	—	—	—
Other Operating Expense	-5	-1	0	—	—	—	—	—
Operating Income	71	-211	-170	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	21	24	17	—	—	—	—	—
Net Income Before Taxes	92	-187	-153	—	—	—	—	—
Income Taxes	5	0	0	—	—	—	—	—
Consolidated Net Income	87	-187	-153	—	—	—	—	—
Net Income From Continuing Operations	87	-187	-153	—	—	—	—	—
Net Income	87	-187	-153	—	—	—	—	—
EPS (Recurring)	2.34	-5.00	-5.20	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	2.34	-5.00	-5.20	—	—	—	—	—
EPS (Diluted)	2.30	-5.00	-5.20	—	—	—	—	—
EBITDA	93	-186	-152	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	8.85	—	—	—	—	—	—	—
Price To Sales Ratio	3.09	146.43	—	—	—	—	—	—
Gross Margin	99.59	100.00	—	—	—	—	—	—
Operating Margin	29.10	-5,275.00	—	—	—	—	—	—
Net Margin	35.66	-4,675.00	—	—	—	—	—	—
Shares Outstanding	37	37	29	—	—	—	—	—
Market Capitalization	753	586	1,153	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tanini Annita	Corp. Controller & VP, Finance	Aug 18 '26	Sale	10.29	1,224	12,595	45,144	Aug 20
Lerner Lorena Raquel	Chief Scientific Officer	Aug 18 '26	Sale	10.29	3,568	36,715	27,559	Aug 20
Cho Esther	Chief Legal Officer	Aug 18 '26	Sale	10.29	4,485	46,151	35,770	Aug 20
Newton Charles W.	Director	Aug 18 '26	Sale	10.30	551	5,675	12,114	Aug 20
BIENAIME JEAN JACQUES	Director	Aug 17 '26	Buy	10.27	1,000	10,270	19,592	Aug 19
BIENAIME JEAN JACQUES	Director	Jul 15 '26	Buy	10.61	1,000	10,610	18,592	Jul 17
BIENAIME JEAN JACQUES	Director	Jun 15 '26	Buy	10.19	1,000	10,190	17,592	Jun 17
Newton Charles W.	Director	Jun 11 '26	Sale	10.04	550	5,522	12,665	Jun 15
Knowles Julius	Director	Jun 04 '26	Sale	10.73	2,625	28,166	10,958	Jun 08
Farzan Nima	Director	Jun 04 '26	Sale	10.73	2,625	28,166	9,767	Jun 08
Seth Alpna	Director	Jun 04 '26	Sale	10.72	2,625	28,140	9,767	Jun 05
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	10.58	1,000	10,580	9,450	May 19
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.